Baxalta, Inc. (BXLT)

Oncology Corporate Profile

HQ Location

One Baxter Parkway
Deerfield, IL 60015

Company Description

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients' lives, Baxalta's broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy.

Website: http://www.baxalta.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
pacritinibJAK2/FLT3 dual inhibitorMyelofibrosisIII
imalumab / BAX 069MIF inhibitorColorectal cancerII
Oncaspar® / pegaspargaseAcute Myelogenous Leukemia (AML)II

View additional information on product candidates here »

Source: http://www.baxalta.com

Recent News Headlines

8/21/2017 06:18 am

8/21/2017 06:18 am

8/21/2017 06:18 am

8/21/2017 06:18 am

8/20/2017 06:18 pm

8/20/2017 06:18 pm

8/20/2017 06:18 pm

7/13/2017 06:17 am

7/12/2017 12:17 pm

7/12/2017 12:17 pm

7/12/2017 12:17 pm

6/12/2017 06:17 am

6/11/2017 12:17 am

6/11/2017 12:17 am

6/11/2017 12:17 am

6/11/2017 12:17 am

5/20/2017 12:17 am

16 companies we lost in 2016

12/20/2016 07:00 pm

5 Biggest Acquisitions of 2016

12/16/2016 06:00 pm